This article is more than 5 years old. Information may no longer be current.

Pfizer revenue up for quarter; latanoprost leading ophthalmic drug

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW YORK — Pfizer’s revenues for the first quarter of 2005 were $13.1 billion, up 5% over revenues in the same quarter of 2004, the company stated in a press release. The company’s latanoprost-based drugs led its ophthalmic line in sales, showing a 19% growth from the previous year.

The glaucoma medications Xalatan (latanoprost) and Xalacom (latanoprost, timolol maleate) had first quarter revenues of $333 million, the company said.

Also during the quarter, the company paid Eyetech Pharmaceuticals a $90 million license fee after the U.S. approval of Macugen (pegaptanib sodium injection) for the treatment of neovascular age-related macular degeneration. According to a financial press release from Eyetech, first quarter 2005 sales of Macugen were $25.4 million.

In March the two companies enrolled the first patient in a phase 4 trial combining Macugen and Novartis’ Visudyne (verteporfin for injection) to determine if patients with the predominantly classic form of neovascular AMD benefit from the combined therapy, according to Eyetech.